Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010
Date:7/28/2009

DETROIT, July 28 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) recorded net sales of $48.1 million in the first quarter of Fiscal 2010, ended June 30, 2009, compared to $108.3 million during the corresponding period of Fiscal 2009. The reduction in sales was primarily due to reduced sales of Para IV products in the current period, as compared to the corresponding period of Fiscal 2009. Sales of distributed products were also lower due to price erosion on the products sold, partially offset by new product launches. Caraco's manufactured product sales in the first quarter of Fiscal 2010 were lower due to the negative impact of our voluntary recalls of certain products, and, in part, the FDA's seizure of certain of our inventory and cessation of manufacturing, as previously disclosed. We incurred a net pre-tax loss of $14.4 million during the first quarter of Fiscal 2010, as compared to net pre-tax income of $14.6 million during the corresponding period of Fiscal 2009. The net pre tax loss was primarily due to the creation of an inventory reserve relating to the inventory seized by the FDA, as well as lower sales.

Dan Movens, Caraco's Chief Executive Officer, said, "As previously disclosed, on June 25, 2009, the FDA seized drug products manufactured in our Michigan facilities. The seizure also included ingredients held at these same facilities. The FDA's most recent inspection of Caraco's Detroit facility, completed in May 2009, found observations of potential unresolved violations of cGMP requirements as previously disclosed in our last SEC filing on Form 10-K for the fiscal year ended March 31, 2009, filed on June 15, 2009. The Company believes that corrective actions have been made and continual improvements are in process. We are working with consultants to further define and correct any
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... high quality access control power suppliers are popular in ... new collection of power suppliers. Additionally, it has launched ... All the new models come with big discounts, up ... 20, 2014. , SWAccessControl.com has thousands of happy customers, ... a long time. It is very wise to visit ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 The FDA ... in Common, **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? ... , The FDA’s focus on promotional activities is no ... , Now they're looking at websites, Twitter, journal articles, ... calendar for Thursday, Dec. 11, for On-Demand access to ...
(Date:11/22/2014)... 2014 Every year AlignLife clinics nationwide ... experience rapid growth in the Greenville, SC area in ... AlignLife of Simpsonville will be partnering with ... first annual Toy Drive. These six offices came together ... with this year's toy drive. With so many amazing ...
(Date:11/22/2014)... black prom dress will never go out of fashion. BellasDress.com, ... new items of black prom gowns . Now all ... up to 70% off. People throughout the world can enjoy ... made with the best materials, can make wearers feel comfortable. ... company provides these beautiful outfits in a huge range of ...
(Date:11/22/2014)... “Due to my knee replacement surgery, I had to ... using the ice grip attachment, I noticed how dangerous the ... be a safer way to prevent possible injuries, so I ... BLOCK offers added safety and stability in slick and icy ... and damage associated with traditional spiked ice grips. As a ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2
... Reporter , WEDNESDAY, Aug. 10 (HealthDay News) -- Tracking Lyme ... of the tick-borne illness in humans, government researchers report. ... be a good indicator of the risk of human infection, ... Prevention said. When blood tests show that few dogs in ...
... If you think teenagers prefer social media over the ... it comes to teens involved in research studies. When ... how they preferred to be contacted about their participation in ... Nearly 54 percent preferred contact via cell and/or land line ...
... , WEDNESDAY, Aug. 10 (HealthDay News) -- The first ... and tested on mice. Now scientists hope the ... current methods used to repair internal anal sphincters, such as ... only limited success. "In essence, we have built ...
... DETROIT A pharmacist-directed anticoagulation service improves the coordination ... for patients treated with the anticoagulant drug warfarin, according ... published online today in the July/August issue of the ... transition of care directed by the anticoagulation service was ...
... Serena Gordon HealthDay Reporter , TUESDAY, Aug. 9 ... a higher risk of developing mild cognitive impairment or dementia, ... who began the study without dementia had 85 percent higher ... next five years if they had 15 or more sleep ...
... , TUESDAY, Aug. 9 (HealthDay News) -- One-third of ... a type of stroke that involves bleeding into the ... (PTSD), researchers have found. The trigger for these ... having another brain hemorrhage, which is most often caused ...
Cached Medicine News:Health News:Tracking Lyme Disease in Dogs May Help Protect Humans 2Health News:Tracking Lyme Disease in Dogs May Help Protect Humans 3Health News:Telephone trumps social media when communicating with teens about research 2Health News:Human Cells Used to Make Replacement Anal Sphincters in Mice 2Health News:Pharmacist-directed anticoagulation service improves care coordination 2Health News:Sleep Apnea Could Up Risk of Dementia In Elderly Women 2Health News:Sleep Apnea Could Up Risk of Dementia In Elderly Women 3Health News:Survivors of Brain Hemorrhage May Experience PTSD 2
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care instruments and consumables for the medical, research, and ... the veterinary and research markets in the ... a stock purchase agreement to acquire 100% of QCR ... based distribution organization. The transaction closed on ...
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
(Date:11/21/2014)... and MELVILLE, N.Y. , ... CAH ), one of the world,s largest health ... HSIC ), the world,s largest provider of health ... and medical practitioners, today announced that the companies have ... of the most comprehensive service and product offerings to ...
Breaking Medicine Technology:Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
... MYL ) today announced that it has ... Valeant Pharmaceuticals. Mylan has acquired the abbreviated new drug ... which is the generic version of Valeant,s BenzaClin ® ... version of this product through a licensing agreement with ...
... Md., Feb. 3, 2012   Citing the significant ... provide over intravenously (IV) administered chemotherapy, Maryland,s cancer community, ... state legislature this week to pass key legislation that ... their prescribed chemotherapy regimen of choice. ...
Cached Medicine Technology:Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant 2Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant 3Maryland's Cancer Care Community, Patient Advocates Urge State Legislature to Create Parity in Coverage for Preferred Cancer Drugs 2
... Stereo Cube is used to diagnose Stereo and ... use of polarized glasses. The test can ... stereopsis, visual attention, form and depth perception. The ... to 450 seconds of arc and is ideal ...
The Lang Stereotest was created to simplify stereopsis screening in children. It is based on two principles: random dots and cylindrical gratings. The Lang Stereotest I measures disparities: Star 600...
... test was developed to test for both crossed ... the more reliable red/green glasses to provide ... dependent on polarizing spectacles which can be quite ... attractive image of a butterfly which makes the ...
... to assist patients with red-green color deficiencies in ... off wavelengths shorter than 582 nm enabling an ... most difficult color distinctions. A color anomalous patient ... a color is in the longer or shorter ...
Medicine Products: